

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (withdrawn, currently amended) A method for the prevention or treatment of diabetes comprising: administering to a human subject in need of prevention or treatment, a pharmaceutical composition comprising a ~~Type 1 diabetes autoantigen~~ human preproinsulin or an immunologically active fragment or variant thereof and ~~an oil-based carrier~~ a Montanide ISA adjuvant or an equivalent thereof.

2.-3. (cancel)

4. (withdrawn, currently amended) The method of claim ~~[[3]]~~ 1, wherein the ~~autoantigen fragment of preproinsulin comprises~~ [[is]] human insulin B-chain or an immunologically active fragment or variant thereof.

5. (withdrawn, currently amended) The method of claim 4, wherein the insulin B-chain fragment comprises amino acids ~~[[33-37]]~~ 33-47 of SEQ ID NO:1.

6. (cancel)

7. (withdrawn) The method of claim 1, wherein the pharmaceutical composition is a vaccine.

8. (withdrawn, currently amended) The method of claim 1, wherein the ~~autoantigen preproinsulin or immunologically active fragment or variant thereof~~ is a synthetic peptide.

9. (withdrawn, currently amended) The method of claim 1, wherein the ~~oil-based carrier is IFA or~~ Montanide ISA adjuvant comprises Montanide 80 or an equivalent composition.

10. (currently amended) A pharmaceutical composition comprising ~~a type 1 diabetes autoantigen~~ human preproinsulin or an immunologically active fragment or variant thereof and ~~an oil-based adjuvant~~ a Montanide ISA adjuvant or an equivalent thereof.

11.-12. (cancel)

13. (currently amended) The pharmaceutical composition of claim ~~[[12]]~~ 10, wherein the ~~autoantigen is~~ fragment of preproinsulin comprises human insulin B-chain or an immunologically active fragment or variant thereof.

14. (currently amended) The pharmaceutical composition of 13, wherein the insulin B-chain fragment comprises amino acids ~~[[33-37]]~~ 33-47 of SEQ ID NO:1.

15. (cancel)

16. (currently amended) The pharmaceutical composition of claim 10, wherein the ~~autoantigen~~ preproinsulin or immunologically active fragment or variant thereof is a synthetic peptide.

17. (currently amended) The pharmaceutical composition of claim 10, wherein the ~~oil-based carrier is IFA or~~ Montanide ISA comprises Montanide 80 or an equivalent composition.

18. (currently amended) The pharmaceutical composition of claim ~~[[13]]~~ 10, wherein the human ~~insulin B-chain~~ preproinsulin or immunologically active fragment or variant thereof is solubilized in urea.

19. (currently amended) A kit for preventing or treating type 1 diabetes, the kit comprising: a human preproinsulin ~~type 1 diabetes autoantigen~~ or immunologically active fragment or variant thereof, ~~an oil-based carrier~~ a Montanide ISA adjuvant, and instructions indicating suitability for human use.

20. (cancel)

21. (currently amended) The kit of claim 19, wherein the human preproinsulin or immunologically active fragment or variant thereof ~~autoantigen~~ is a synthetic peptide.

22. (currently amended) The kit of claim 19, wherein the human preproinsulin or immunologically active fragment or variant thereof ~~autoantigen~~ is lyophilized.

23. (currently amended) The kit of claim 19, wherein the ~~autoantigen is~~ fragment of preproinsulin comprises human insulin B-chain or an immunologically active fragment or variant thereof.

24. (currently amended) The kit of claim 19, wherein the ~~oil-based carrier is IFA or~~ Montanide ISA comprises Montanide 80 or an equivalent composition.

25. (withdrawn, currently amended) A method of enabling a health care provider to prevent or treat type 1 diabetes in a human subject, the method comprising:

providing a health care provider with a composition comprising a human diabetes type 1 autoantigen preproinsulin or immunologically active fragment or variant thereof and a Montanide ISA; and

~~optionally providing the health care provider with an oil-based carrier; and~~
providing the health care provider with instructions for use of the composition autoantigen to treat the subject.

26. (cancel)

27. (withdrawn, currently amended) The method of claim 25, wherein the autoantigen human preproinsulin or immunologically active fragment or variant thereof is a synthetic peptide.

28. (withdrawn, currently amended) The method of claim 25, wherein the autoantigen human preproinsulin or immunologically active fragment or variant thereof is lyophilized.

29. (cancel)

30. (withdrawn, currently amended) The method of claim 25, wherein the ~~oil-based carrier is IFA or~~ Montanide ISA comprises Montanide 80 or an equivalent composition.

31. (new) The method of claim 1, wherein the variant differs from SEQ ID NO:1 at no more than 20% of the amino acid residues.

32. (new) The pharmaceutical composition of claim 10, wherein the variant differs from SEQ ID NO:1 at no more than 20% of the amino acid residues.

33. (new) The kit of claim 19, wherein the variant differs from SEQ ID NO:1 at no more than 20% of the amino acid residues.

34. (new) The method of claim 25, wherein the variant differs from SEQ ID NO:1 at no more than 20% of the amino acid residues.